CanSino Biologics Future Growth
Future criteria checks 5/6
CanSino Biologics is forecast to grow earnings and revenue by 141.4% and 33.3% per annum respectively. EPS is expected to grow by 123.9% per annum. Return on equity is forecast to be 5.4% in 3 years.
Key information
141.4%
Earnings growth rate
123.9%
EPS growth rate
| Biotechs earnings growth | 43.4% |
| Revenue growth rate | 33.3% |
| Future return on equity | 5.4% |
| Analyst coverage | Low |
| Last updated | 02 Nov 2024 |
Recent future growth updates
Recent updates
CanSino Biologics Inc.'s (HKG:6185) Price Is Right But Growth Is Lacking After Shares Rocket 37%
Nov 11
Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?
Jun 20The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically
Apr 07Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?
Feb 06CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?
Oct 13Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be
Sep 07CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?
May 12Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?
Jan 09CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up
Sep 16Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade
Aug 31Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?
Aug 29Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts
Jul 13Is CanSino Biologics (HKG:6185) Using Too Much Debt?
Jul 01We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt
Mar 15Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,659 | 136 | 332 | 592 | 4 |
| 12/31/2025 | 1,205 | -50 | -28 | 356 | 5 |
| 12/31/2024 | 896 | -195 | -136 | 105 | 2 |
| 9/30/2024 | 749 | -720 | -936 | -447 | N/A |
| 6/30/2024 | 635 | -867 | -940 | -385 | N/A |
| 3/31/2024 | 371 | -1,513 | -1,201 | -671 | N/A |
| 12/31/2023 | 357 | -1,483 | -1,519 | -908 | N/A |
| 9/30/2023 | 503 | -1,420 | -1,867 | -1,207 | N/A |
| 6/30/2023 | 431 | -1,763 | -2,339 | -1,375 | N/A |
| 3/31/2023 | 636 | -1,170 | -2,660 | -1,599 | N/A |
| 12/31/2022 | 1,035 | -909 | -2,927 | -1,852 | N/A |
| 9/30/2022 | 1,921 | 106 | -1,733 | -587 | N/A |
| 6/30/2022 | 2,868 | 989 | -992 | 68 | N/A |
| 3/31/2022 | 4,332 | 2,050 | 328 | 1,464 | N/A |
| 12/31/2021 | 4,300 | 1,914 | 847 | 2,050 | N/A |
| 9/30/2021 | 3,105 | 1,113 | 18 | 1,065 | N/A |
| 6/30/2021 | 2,082 | 643 | -250 | 531 | N/A |
| 3/31/2021 | 488 | -388 | -873 | -317 | N/A |
| 12/31/2020 | 25 | -397 | -638 | -350 | N/A |
| 9/30/2020 | 6 | -239 | -413 | -230 | N/A |
| 6/30/2020 | 4 | -189 | -333 | -196 | N/A |
| 3/31/2020 | 6 | -135 | -310 | -164 | N/A |
| 12/31/2019 | 2 | -157 | -271 | -154 | N/A |
| 9/30/2019 | 6 | -137 | -265 | -131 | N/A |
| 6/30/2019 | 11 | -156 | -280 | -140 | N/A |
| 3/31/2019 | 9 | -158 | -252 | -132 | N/A |
| 12/31/2018 | 9 | -138 | -284 | -124 | N/A |
| 12/31/2017 | 9 | -64 | N/A | -56 | N/A |
| 12/31/2016 | 8 | -50 | N/A | -34 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6185 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: 6185 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 6185 is expected to become profitable in the next 3 years.
Revenue vs Market: 6185's revenue (33.3% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 6185's revenue (33.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6185's Return on Equity is forecast to be low in 3 years time (5.4%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 21:32 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CanSino Biologics Inc. is covered by 19 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Lijian Zhao | China International Capital Corporation Limited |
| Hangci Zheng | China International Capital Corporation Limited |